These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7447951)

  • 21. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
    Lautala P; Ulmanen I; Taskinen J
    Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
    Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
    Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methoxytyrosine formation as an indicator of catechol-O-methyltransferase activity in rat liver in vivo.
    Kehr W; Zimmermann R; Thiede M
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Oct; 300(1):19-23. PubMed ID: 593428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].
    Kulisevsky J
    Neurologia; 1999; 14(7):349-58. PubMed ID: 10570622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of catechol-O-methyl transferase in the metabolism of the putative dopamine autoreceptor agonist 3-PPP(3-(3-hydroxyphenyl)-N-n-propylpiperidine).
    Bhaird NN; Fowler CJ; Thorberg O; Tipton KF
    Biochem Pharmacol; 1985 Oct; 34(19):3599-601. PubMed ID: 4052101
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M; Kettler R; Zürcher G; Schaffner R; Haefely WE
    Eur Neurol; 1987; 27 Suppl 1():9-20. PubMed ID: 3123242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Variation in hepatic membrane-bound catechol-O-methyltransferase activity in Fischer and Wistar-Furth strains of rat.
    Roth JA; Grossman MH; Adolf M
    Biochem Pharmacol; 1990 Sep; 40(5):1151-3. PubMed ID: 2390111
    [No Abstract]   [Full Text] [Related]  

  • 31. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioenzymatic assay of femtomole concentrations of DOPA in tissues and body fluids.
    Zürcher G; Da Prada M
    J Neurochem; 1979 Sep; 33(3):631-9. PubMed ID: 479880
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence for the methylation of apomorphine by catechol-O-methyl-transferase in vivo and in vitro.
    McKenzie GM; White HL
    Biochem Pharmacol; 1973 Sep; 22(18):2329-36. PubMed ID: 4739044
    [No Abstract]   [Full Text] [Related]  

  • 34. The purification and kinetic properties of liver microsomal-catechol-o-methyltransferase.
    Borchardt RT; Cheng CF; Cooke PH
    Life Sci; 1974 Mar; 14(6):1089-1100. PubMed ID: 4822918
    [No Abstract]   [Full Text] [Related]  

  • 35. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man.
    Schwartz DE; Brandt R
    Arzneimittelforschung; 1978; 28(2):302-7. PubMed ID: 580398
    [No Abstract]   [Full Text] [Related]  

  • 37. Catechol-O-methyltransferase activity: a determinant of levodopa response.
    Reilly DK; Rivera-Calimlim L; Van Dyke D
    Clin Pharmacol Ther; 1980 Aug; 28(2):278-86. PubMed ID: 7398195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents.
    Raxworthy MJ; Youde IR; Gulliver PA
    Xenobiotica; 1986 Jan; 16(1):47-52. PubMed ID: 2868577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased erythrocyte catechol-O-methyltransferase activity in elderly: relationship to clinical peculiarities in Parkinson's disease?
    Maltête D; Edouard T; Mihout B; Costentin J
    Int J Geriatr Psychiatry; 2010 Mar; 25(3):323-4. PubMed ID: 20148410
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.